The Goldman Sachs Group Lowers Seres Therapeutics (NASDAQ:MCRB) Price Target to $0.75

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) had its price objective dropped by The Goldman Sachs Group from $1.00 to $0.75 in a report issued on Friday,Benzinga reports. The firm currently has a "sell" rating on the biotechnology company's stock. The Goldman Sachs Group's price objective indicates a potential upside of 0.44% from the stock's current price.

Several other research firms have also recently weighed in on MCRB. StockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, March 6th. Canaccord Genuity Group restated a "buy" rating and issued a $10.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 14th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $4.00.

Seres Therapeutics Trading Up 1.2 %

Shares of Seres Therapeutics stock traded up $0.01 during mid-day trading on Friday, reaching $0.75. 1,332,267 shares of the stock were exchanged, compared to its average volume of 3,439,005. The company has a market cap of $130.01 million, a price-to-earnings ratio of -3.25 and a beta of 2.19. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53. The firm has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.83.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MCRB. Charles Schwab Investment Management Inc. raised its holdings in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock valued at $708,000 after purchasing an additional 222,771 shares during the last quarter. FMR LLC raised its holdings in shares of Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock valued at $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Providence Wealth Advisors LLC raised its holdings in shares of Seres Therapeutics by 29.2% in the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 22,250 shares during the last quarter. State Street Corp raised its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after purchasing an additional 43,700 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock valued at $1,314,000 after purchasing an additional 255,014 shares during the last quarter. Institutional investors own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.